<DOC>
	<DOCNO>NCT01480310</DOCNO>
	<brief_summary>This Phase Ia , randomize , double-blind , placebo-controlled , single ascend dose ( SAD ) study male female healthy volunteer , age 18-55 year , enrol single study site Canada .</brief_summary>
	<brief_title>Study Investigate Safety , Pharmacokinetics , Immunogenicity Subcutaneous MCAF5352A Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Total body weight 45 110 kg Vital sign within follow range : oral body temperature 35°C 37.5°C , systolic blood pressure 90 140 mmHg , diastolic blood pressure 50 90 mmHg , pulse rate 45 100 bpm Laboratory test parameter within normal reference range safety laboratory Female subject : Willing use two effective method contraception screen minimum 4 month last dose study drug . Reliable form contraception include oral hormonal contraceptive , patch hormonal contraceptive , vaginal ring , intrauterine device , physical doublebarrier method , surgical hysterectomy , vasectomy male partner . Pregnant lactate woman Administration live , attenuated vaccine within 30 day Day 1 anticipation live attenuated vaccine require within 100 day Day 1 Subjects may receive influenza vaccination influenza season ( approximately October March ) . Subjects must receive live attenuate influenza vaccine within 30 day prior Day 1 time study . Any major illness within 30 day prior Day 1 Clinically significant illness require treatment within 14 day prior Day 1 History clinically significant ECG abnormality know family history cardiac conduction system disease Positive test result indicate current past infection human immunodeficiency virus ( HIV1 2 ) , hepatitis B virus ( hepatitis B surface antigen [ HBsAg ] , hepatitis B core antibody [ antiHBc ] ) , hepatitis C virus ( HCV ) Positive screen test latent mycobacterial infection within 2 month precede Day 1 without evidence complete course antitubercular therapy previous BCG vaccination History significant chronic recurrent infection History clinically significant drug allergy and/or know hypersensitivity protein therapeutic formulation component related drug History alcohol drug abuse within 12 month prior Day 1 , evidence abuse indicate specific screen laboratory test result , alcohol consumption 14 unit alcohol per week Positive breathalyzer alcohol urine screen result drug abuse , prescription medication Subjects previously receive study drug Participation clinical trial within 4 week Day 1 use experimental biologic therapy within 12 week prior Day 1 within 5 halflives product , whichever great Use prescription drug within 14 day prior Day 1 study , except hormonal contraceptive hormone replacement therapy Use overthecounter ( OTC ) medication within 7 day prior Day 1 study . Medications acetaminophen ibuprofen routinelytaken dietary supplement , include vitamin herbal supplement allow discretion investigator provide medication question discernible impact study . Donation plasma within 7 day prior Day 1 . Donation loss blood 50 mL 499 mL blood within 30 day , 499 mL within 56 day prior Day 1 . Lack peripheral venous access Known history mental illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>